Integrating pharmacists into aged care facilities to improve the quality use of medicine (PiRACF Study): protocol for a cluster randomised controlled trial.
Aged care
Care home
Cluster randomised controlled trial
Elderly
Pharmacists
Potentially inappropriate medicine
Quality use of medicines
Residential aged care facility
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
11 Jun 2021
11 Jun 2021
Historique:
received:
25
08
2020
accepted:
21
05
2021
entrez:
12
6
2021
pubmed:
13
6
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Medication management in residential aged care facilities is an ongoing concern. Numerous studies have reported high rates of inappropriate prescribing and medication use in aged care facilities, which contribute to residents' adverse health outcomes. There is a need for new models of care that enhance inter-disciplinary collaboration between residential aged care facility staff and healthcare professionals, to improve medication management. Pilot research has demonstrated the feasibility and benefits of integrating a pharmacist into the aged care facility team to improve the quality use of medicines. This protocol describes the design and methods for a cluster randomised controlled trial to evaluate the outcomes and conduct economic evaluation of a service model where on-site pharmacists are integrated into residential aged care facility healthcare teams to improve medication management. Intervention aged care facilities will employ on-site pharmacists to work as part of their healthcare teams 2 to 2.5 days per week for 12 months. On-site pharmacists, in collaboration with facility nurses, prescribers, community pharmacists, residents and families will conduct medication management activities to improve the quality use of medicines. Aged care facilities in the control group will continue usual care. The target sample size is 1188 residents from a minimum of 13 aged care facilities. The primary outcome is the appropriateness of prescribing, measured by the proportion of residents who are prescribed at least one potentially inappropriate medicine according to the 2019 Beers Criteria. Secondary outcomes include hospital and emergency department presentations, fall rates, prevalence and dose of antipsychotics and benzodiazepines, Anticholinergic Cognitive Burden Score, staff influenza vaccination rate, time spent on medication rounds, appropriateness of dose form modification and completeness of resident's allergy and adverse drug reaction documentation. A cost-consequence and cost-effectiveness analysis will be embedded in the trial. The results of this study will provide information on clinical and economic outcomes of a model that integrates on-site pharmacists into Australian residential aged care facilities. The results will provide policymakers with recommendations relevant to further implementation of this model. ACTRN12620000430932 . Registered on 1 April 2020 with ANZCTR.
Sections du résumé
BACKGROUND
BACKGROUND
Medication management in residential aged care facilities is an ongoing concern. Numerous studies have reported high rates of inappropriate prescribing and medication use in aged care facilities, which contribute to residents' adverse health outcomes. There is a need for new models of care that enhance inter-disciplinary collaboration between residential aged care facility staff and healthcare professionals, to improve medication management. Pilot research has demonstrated the feasibility and benefits of integrating a pharmacist into the aged care facility team to improve the quality use of medicines. This protocol describes the design and methods for a cluster randomised controlled trial to evaluate the outcomes and conduct economic evaluation of a service model where on-site pharmacists are integrated into residential aged care facility healthcare teams to improve medication management.
METHODS
METHODS
Intervention aged care facilities will employ on-site pharmacists to work as part of their healthcare teams 2 to 2.5 days per week for 12 months. On-site pharmacists, in collaboration with facility nurses, prescribers, community pharmacists, residents and families will conduct medication management activities to improve the quality use of medicines. Aged care facilities in the control group will continue usual care. The target sample size is 1188 residents from a minimum of 13 aged care facilities. The primary outcome is the appropriateness of prescribing, measured by the proportion of residents who are prescribed at least one potentially inappropriate medicine according to the 2019 Beers Criteria. Secondary outcomes include hospital and emergency department presentations, fall rates, prevalence and dose of antipsychotics and benzodiazepines, Anticholinergic Cognitive Burden Score, staff influenza vaccination rate, time spent on medication rounds, appropriateness of dose form modification and completeness of resident's allergy and adverse drug reaction documentation. A cost-consequence and cost-effectiveness analysis will be embedded in the trial.
DISCUSSION
CONCLUSIONS
The results of this study will provide information on clinical and economic outcomes of a model that integrates on-site pharmacists into Australian residential aged care facilities. The results will provide policymakers with recommendations relevant to further implementation of this model.
TRIAL REGISTRATION
BACKGROUND
ACTRN12620000430932 . Registered on 1 April 2020 with ANZCTR.
Identifiants
pubmed: 34116708
doi: 10.1186/s13063-021-05335-0
pii: 10.1186/s13063-021-05335-0
pmc: PMC8193166
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
390Références
Australas J Ageing. 2019 Sep;38 Suppl 2:9-25
pubmed: 31496065
J Clin Pharm Ther. 2019 Aug;44(4):595-602
pubmed: 30793340
Clin Geriatr Med. 2012 May;28(2):173-86
pubmed: 22500537
Australas J Ageing. 2016 Dec;35(4):262-265
pubmed: 26970209
J Am Geriatr Soc. 2019 Apr;67(4):674-694
pubmed: 30693946
Drugs Aging. 2018 Jan;35(1):83-91
pubmed: 29322470
Med J Aust. 2018 May 21;208(9):398-403
pubmed: 29747564
Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):699-707
pubmed: 20583208
Drugs Aging. 2014 Nov;31(11):825-35
pubmed: 25187228
Res Social Adm Pharm. 2020 Sep;16(9):1220-1227
pubmed: 31843360
Behav Res Methods. 2009 Nov;41(4):1149-60
pubmed: 19897823
Ann Pharmacother. 2012 Jul-Aug;46(7-8):972-82
pubmed: 22786837
Aust Fam Physician. 2010 Jun;39(6):413-6
pubmed: 20628681
Implement Sci. 2012 Mar 22;7:23
pubmed: 22436121
Int J Qual Health Care. 2019 May 1;31(4):298-306
pubmed: 30113692
J Clin Med. 2019 Nov 04;8(11):
pubmed: 31689908
Med J Aust. 2002 Aug 19;177(4):189-92
pubmed: 12175322
J Eval Clin Pract. 2011 Feb;17(1):97-103
pubmed: 20825538
Australas J Ageing. 2020 Sep;39(3):e466-e471
pubmed: 32124547
Br J Clin Pharmacol. 2019 Dec;85(12):2668-2688
pubmed: 31465121
Am J Geriatr Pharmacother. 2007 Dec;5(4):345-51
pubmed: 18179993
Lancet. 2007 Jul 14;370(9582):173-184
pubmed: 17630041
Int J Environ Res Public Health. 2018 Mar 12;15(3):
pubmed: 30720779
Drugs Aging. 2016 Mar;33(3):199-204
pubmed: 26961696
J Am Med Dir Assoc. 2017 Jun 1;18(6):470-488
pubmed: 28242191
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Res Social Adm Pharm. 2018 Mar;14(3):228-240
pubmed: 28506574
Br J Clin Pharmacol. 2001 Jun;51(6):523-9
pubmed: 11422011
Res Nurs Health. 2008 Feb;31(1):42-51
pubmed: 18163447
Int J Qual Health Care. 2018 Dec 1;30(10):810-816
pubmed: 29889231
Ann Pharmacother. 2014 Nov;48(11):1425-33
pubmed: 25159001
Alzheimer Dis Assoc Disord. 2019 Oct-Dec;33(4):331-338
pubmed: 31343414
J Palliat Med. 2018 Oct;21(10):1472-1479
pubmed: 30106321
Aust N Z J Psychiatry. 2019 Feb;53(2):136-147
pubmed: 29488403
Can Pharm J (Ott). 2014 Jul;147(4):209-32
pubmed: 25360148
Pharmacy (Basel). 2019 Jun 06;7(2):
pubmed: 31174405
Drugs. 2009;69(4):393-406
pubmed: 19323584
Eur J Clin Pharmacol. 2020 Mar;76(3):319-335
pubmed: 31832732
Pharmacol Res. 2017 Feb;116:20-28
pubmed: 27965033
Drug Saf. 2011 Jul 1;34(7):567-75
pubmed: 21663332
Geriatr Gerontol Int. 2014 Oct;14(4):934-41
pubmed: 24299444
Australas J Ageing. 2019 Jun;38(2):132-135
pubmed: 30656806
Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):361-71
pubmed: 23277778
Medicines (Basel). 2020 Apr 20;7(4):
pubmed: 32326013
J Clin Pharm Ther. 2011 Feb;36(1):33-44
pubmed: 21198718
J Am Geriatr Soc. 2011 Aug;59(8):1521-30
pubmed: 21797829
J Am Geriatr Soc. 2020 Feb;68(2):305-312
pubmed: 31681981
J Clin Pharm Ther. 2018 Aug;43(4):591-593
pubmed: 29781222
Pharm World Sci. 2009 Apr;31(2):216-23
pubmed: 19242818
J Am Coll Dent. 2014 Summer;81(3):14-8
pubmed: 25951678
Curr Drug Saf. 2017 Feb 09;:
pubmed: 28183240
Cochrane Database Syst Rev. 2016 Feb 12;2:CD009095
pubmed: 26866421
Br J Clin Pharmacol. 2012 Oct;74(4):573-80
pubmed: 22607195
Ann Pharmacother. 2019 Oct;53(10):1005-1019
pubmed: 31129978
Int Psychogeriatr. 2016 Jun;28(6):977-82
pubmed: 26775538